Allogeneic transplantation in patients with acute lymphoblastic leukaemia in first remission (ALL-CR1) has been studied in several clinical trials. However, no pooled survival analysis has yet been done. We conducted a survival meta-analysis to compare allogeneic transplantation vs chemotherapy or autologous transplantation using an intention-to-treat approach. Our study included the controlled clinical trials, wherein allocation to allogeneic transplant was based on donor availability. The event-free individual survival data were reconstructed on the basis of published information and Kaplan-Meier graphs. We then generated the meta-analytic event-free survival curves for the two treatments. The mean survival gain per patient was estimated and a simplified cost-effectiveness assessment was carried out. In the allogeneic transplantation group, 293 patients were examined and 479 as controls (four trials). The event-free survival difference was statistically significant (P ¼ 0.011). The relative risk for event occurrence was 0.79 for the experimental group vs the controls (95% CI: 0.66-0.96; P ¼ 0.017). The mean survival gain was 1 year per patient. The cost per life-year gained was less than the conventional threshold of h50 000. Allogeneic transplantation in ALL-CR1 improves event-free survival as compared to chemotherapy or autologous transplantation. Its cost-effectiveness profile is acceptable.
Introduction
ALL represents approximately 20% of acute leukaemias in adults. With induction treatment, 80-90% of patients achieve CR, but the majority relapse and so the long-term event-free survival is only 30-35%. [1] [2] [3] [4] [5] Thus, selecting optimal post-remission treatments is still a matter of debate.
Allogeneic transplantation has been employed as consolidation treatment in ALL for about 20 years, but its effectiveness is limited by severe morbidity. This therapeutic option for patients in CR1 has been studied in a limited number of clinical trials with controversial results. 4, 5 Trials cannot be easily conducted in this disease; enrolment is slow due to the rarity of this leukaemia, and the consequently long enrolment interval (that typically covers up to an entire decade) enhances the heterogeneity of the clinical material.
A narrative review 4 and a meta-analysis 5 on crude death rates have been published recently on this topic. In this context, to explore this therapeutic issue further, we carried out a survival meta-analysis comparing allogeneic transplantation vs standard chemotherapy or autologous transplantation and determined the cost-effectiveness profile of allogeneic transplant.
Methods

Study design
The aim of our study was to evaluate the clinical trials conducted in patients with ALL in CR1 and to compare clinical outcomes in terms of survival for the following two therapeutic options: (a) allogeneic transplantation; (b) standard chemotherapy or autologous transplantation. The studies comparing these two treatments were identified through a standard MEDLINE search. Our survival metaanalysis was then carried out as follows. First, the patientlevel information on survival was retrieved from the cohorts enrolled in the various studies. The difference in survival between allogeneic transplant and either autologous transplant or standard chemotherapy was then assessed by pooling the individual survival data across the pertinent studies and by constructing the two meta-analytic survival curves for patients given allogeneic transplant and for the controls, respectively.
A simplified economic analysis of our clinical results estimated the cost per life-year gained using allogeneic transplantation as opposed to the reference treatments. Cost data for this analysis were derived from published information on costs.
Literature search
The clinical trials included in our study were identified by an electronic search of two indexing systems: (a) MED-LINE (PubMed Database: 'http://www.pubmed.org', search from 1 January 2000 to 31 March 2007, keywords: 'transplant*' AND ('acute lymphoblastic leukaemia' OR 'acute lymphoblastic leukemia'); and (b) IDIS compact disks (Iowa Drug Information System, Iowa City, IA, USA; computer search from January 2000 to March 2007). The articles identified in this process were surveyed for additional and earlier citations. Inclusion of studies in our analysis was decided by a simple majority of the reviewers (BB, CO, and AM), who independently read the methods sections of the pertinent papers and applied the stated criteria. Only studies published in English were considered.
In contrast, the studies presenting economic data on the cost of these therapeutic interventions were identified through a separate MEDLINE search. For this purpose, PubMed was scanned (date limits: 1 January 2000-31 March 2007; language ¼ English) using the search terms ('cost*'[titl] OR 'economic'[titl]) AND (allogeneic OR stem-cell). Conversions between different currencies were handled using the Oanda website (http://www.oanda.com). Year of costing was assumed to be 2002 (day ¼ 1 January; exchange rate of EUR to USD on this day ¼ 1.1218).
Selection criteria and inclusion of the clinical studies in our analysis Phase 1. Studies that met all of the following criteria were considered eligible for our analysis: (a) study population of adult patients (ageX18 years) diagnosed with ALL in CR1; (b) presence of an experimental arm treated with allogeneic transplantation and a control group treated with either standard chemotherapy or autologous transplantation; (c) outcome assessment inclusive of either event-free survival (event ¼ death or relapse) or overall survival.
Phase 2. The studies identified through our Phase 1 were inspected to determine whether they met all of the following criteria: (a) minimum follow-up duration of 2 years; (b) intention-to-treat design; (c) assignment to allogeneic transplant based on donor availability, that is natural (or genetic) randomization; although natural randomization may be a potential source of bias, this is the only randomization method that can be employed in this type of clinical research.
In the selection of the outcome index for our systematic review, we planned to examine whether the individual studies included in our analysis had reported survival or event-free survival (or both) and to subsequently choose the outcome measure (event-free survival or overall survival) used most frequently. Event-free survival was more frequent than overall survival. Before excluding those studies that reported only overall survival and not eventfree survival from our analysis, we discussed each of these studies individually to decide whether sufficient information was available in the paper to reconstruct event-free survival.
In performing a meta-analysis, quality assessment of individual trials is mainly based on the method of randomization and on the degree of concealment of the patients' group assignments (for example see the guidelines of the Cochrane Collaboration at http://www.cochrane. org). In the case of allogeneic transplantation, natural randomization is a piece of information that cannot be kept blinded. For this reason, no systematic method of quality assessment was employed in our meta-analysis, and we relied only on a subjective assessment of the overall quality of the studies (rated as excellent, good, sufficient or poor); the main criteria for this subjective assessment included quality of the survival curves, real adoption of an intentionto-treat approach, completeness of data reporting and presence (in the text or in the curves) of the absolute number of censored patients along with the absolute number of deaths.
These scores were separately assigned by three reviewers who empirically used the above-mentioned criteria (CO, BB, AM). When studies were rated as either sufficient or poor, the reason for this low score was recorded.
Meta-analysis of survival data Our survival meta-analysis was performed using individual patient information, [6] [7] [8] [9] that is survival length and status at the last contact. In particular, the data of individual survivals were derived either from the original raw data provided by the trial's authors or from the information contained in the original survival graphs. A number of survival meta-analyses have already been published, [10] [11] [12] [13] [14] [15] [16] [17] in which approximated methods have been used to reconstruct individual survival times from published information (such as the Kaplan-Meier graphs, the text of the article, the tables showing patients at risk at various follow-up times and so on). Formal methods have also been reported wherein a computer program is used to analyse KaplanMeier graphs to estimate the time distribution of the events and of the terminations of the follow-up. 10, 18 In the present work, we estimated the individual eventfree survival times of both patient groups (the group given allogeneic transplant and the controls) and the timing of the events from explicit information published in the studies examined. After obtaining these survival data for all subjects enrolled in the pertinent studies, our analysis generated a pooled (or meta-analytic) survival curve for the allogeneic transplantation group regimens and a pooled survival curve for the controls. In the survival comparison between the two treatments, standard survival methods (Kaplan--Meier analysis) and standard techniques for univariate or multivariate testing were used (log-rank test or Cox model for multivariate relative risk estimation, respectively).
In comparing survival between the two treatments, the mean survival gain (inclusive of censorization and truncated at 12 years) was estimated from the two respective areas under the curve. These areas were estimated by the trapezoidal rule.
The Cox statistics (which considered the effect on survival of two variables: 'type of treatment' introduced as a categorical variable stratified on two levels; and 'study', introduced as a categorical variable stratified on as many levels as the number of trials included in the analysis) was used to calculate the following indexes: (a) the relative risk of event occurrence for the experimental group vs the controls, which was the primary outcome measure of our meta-analysis in comparing the two types of treatment with one another; and (b) the study-specific values of relative risk of event occurrence (that do not depend on the effect of the type of treatment but quantify the degree of heterogeneity between individual trials). Risks were estimated along with their 95% confidence intervals (95% CIs).
In a secondary analysis, the meta-analytic comparison between allogeneic transplantation and the control treatment was re-assessed using trial-specific aggregate survival data, without constructing patient-level information. The statistical method utilized for this secondary analysis has been described previously 10 and reflects a traditional approach for conducting a survival meta-analysis with no access to individual patient data. Its application produced a meta-analytic relative risk of event occurrence for allogeneic transplantation regimens vs the control treatment (along with its 95% CI and the level of statistical significance).
Cost-effectiveness analysis
Costs were considered to reflect only the expenditure of health care resources (that is, direct costs and not indirect expenses such as wages or productivity lost because of illness or death). This approach is the most commonly used in the analysis published in recent years. Cost-minimization analysis is appropriate for comparing equi-effective treatments, whereas cost-effectiveness analysis is indicated when there is a significant difference in clinical effectiveness. 11 Our study utilized a cost-effectiveness analysis because allogeneic transplantation proved to be significantly more effective than the reference treatments. Our cost-effectiveness analysis was designed to determine the incremental cost-effectiveness ratio, that is the ratio of incremental cost and incremental effectiveness (where incremental cost is the lifetime cost difference per patient between allogeneic transplantation and standard chemotherapy or autologous transplantation and incremental effectiveness is the lifetime survival difference per patient between the two treatments). This ratio is expressed as cost per life-year gained.
Sensitivity analyses were carried out to reflect the main variations in these parameters resulting from our literature search.
Results
Clinical material
Our clinical search on MEDLINE extracted 226 studies. Only seven clinical trials [1] [2] [3] [19] [20] [21] [22] met the criteria set by Phase 1 of our meta-analysis protocol. In Phase 2, we first excluded the trial by Hallbook et al. 20 (in which the subjects were given either autologous or allogeneic transplantation according to no pre-specified criteria and without using an intention-to-treat design). On the other hand, the studies by Dombret et al. 22 and Gupta et al. 1 were a matter of controversy; in fact, the experimental arm of these two trials enrolled not only a vast majority of patients receiving a transplant from a related donor (N ¼ 46 and N ¼ 39 in the studies of Dombret et al. 22 and Gupta et al., 1 respectively) but also a small patient subgroup transplanted from unrelated donors (N ¼ 14 and N ¼ 9, respectively). To complicate this issue further, Dombret et al. 22 stated in their paper that their two subgroups of 46 and 14 patients had a similar survival pattern (so that their Figure 1 did not separately present the two respective Kaplan-Meier curves, but showed a single curve based on the overall population of 46 þ 14 patients). Likewise, in their survival analysis, Gupta et al. 1 did not differentiate between the two subgroups transplanted from either related or unrelated donors.
To adhere strictly to the criteria set by our Phase 2, the trials by Dombret et al. 22 and by Gupta et al. 1 were excluded. Hence, our meta-analysis considered a total of four trials 2, 3, 19, 21 (see Table 1 ). The last column of Table 1 shows the subjective quality scores that the three reviewers (CO, BB, AM) assigned to the four clinical studies.
Meta-analysis
The overall number of patients enrolled in the four trials was 293 for the allogeneic transplantation group (donor group) and 479 for the control group (no-donor group). The size of these two patient groups reflects our two criteria of genetic randomization and intention-to-treat approach. Table 2 shows the number of patients who actually underwent transplantation in the donor group and in the no-donor group.
In the majority of cases, our reconstruction of individual patient data was directly based on the Kaplan-Meier Table 1 Randomised studies included in the meta-analysis Figure 3 of this paper shows the Kaplan-Meier curve of relapses over time (without considering deaths as events), whereas, in general, it is preferable to construct event-free Kaplan-Meier curves in which the event can be either a relapse or a death.
graphs, the timing of the downward steps in the curve, the tickmarks indicating censored cases (as well as on narrative information reported by the respective authors). When these sources of information were insufficient, a computerized analysis was run 18 to obtain a better estimation of individual survival times. Supplemental information on individual patient data is available as a MS-Word file at http://www.wwwlabsifo.org/supplements/allogeneic-sctin-all.doc. In particular, this web file presents detailed information on the methods that we used to reconstruct these data.
Our survival meta-analysis based on individual patient data yielded the two event-free survival curves shown in Figure 1 . The survival rates (7s.e.) for the experimental group were 63.5% (72.8%) at 1 year, 50.3% (72.9%) at 2 years, 47.4% (72.9%) at 3 years, 45.6% (72.9%) at 4 years, 45.2% (72.9%) at 5 years, 44.2% (72.9%) at 7 years, and 43.2% (73.1%) at 10 years. Those for the control group were 60.7% (72.2%) at 1 year, 47.9% (72.3%) at 2 years, 41.6% (7 2.3%) at 3 years, 38.2% (72.2%) at 4 years, 36.7% (72.2%) at 5 years, 35.4% (72.2%) at 6 years, 31.6% (72.2%) at 7 years.
As judged by the log-rank test, the survival difference between the two treatments was statistically significant (w 2 ¼ 6.54 with 1 d.f., P ¼ 0.011). Likewise, the Cox statistics calculated a relative risk for event occurrence of 0.79 for the experimental group vs the controls (95% CI: 0.66-0.96; P ¼ 0.017). Figure 2 shows the meta-analytic relative risk (with 95% CI) along with the four studyspecific risks.
Mean event-free survival times per patient (with survival times truncated at 12 years) were 5.88 years in the allogeneic transplant group and 4.88 years in the control group. These two figures yielded a mean event-free survival gain of 1 year per patient. Since in the long-term prognosis of this disease condition, event-free survival tends to be inter-exchangeable with overall survival, allogeneic transplant was assumed to yield a mean survival gain of 1 year per patient.
In our assessment of the inter-trial heterogeneity (Cox model), the study-specific values of relative event risk were those shown in Figure 3 . All of these relative risks were calculated in comparison with the study by Thomas et al.
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(which was chosen as a reference with death risk ¼ 1, because this trial had enrolled the largest patient population). These data on heterogeneity indicate that, in comparison with the reference study, the trial by Hunault et al. 21 showed a significantly better event-free survival pattern (relative risk ¼ 0.77 with Po0.05). The two studies by Ribera et al. 3 and Labar et al. 19 showed virtually no heterogeneity.
In the meta-analysis based on aggregate survival data, the meta-analytic relative risk of event occurrence for Table 2 Number of patients who actually underwent transplantation in the donor group and in the no-donor group of the four randomized studies 
Cost assessments
Our economic search on MEDLINE extracted a total of 102 studies. After inspection of each of these studies, four papers [23] [24] [25] [26] were found to be pertinent for our analysis. As regards allogeneic SCT, Mishra et al. 23 estimated the cost incurred by 17 patients in Norway; these authors analysed pre-transplant procedures, transplantation and 1-year follow-up costs; sources of cost included harvesting, personnel costs, clinical and laboratory procedures, along with blood products and drugs related to patients and donors. The mean cost was found to be $106 825 per patient (range of $: 42 376-362 430).
In the study conducted by Lee et al. 24 in the United States, allogeneic transplantation was reported to cost $105 300 per patient with a range of $32 500 to 338 000 (that is h93 867; range: h28 971-301 301); 181 patients were examined.
In a study conducted by Van Agthoven et al. 25 in the Netherlands, the average cost for allogeneic transplantation was h103 509 (inclusive of donor identification expenses) in a case series (N ¼ 47) that included only patients alive after 2 years of follow-up.
Yu et al. 26 analysed the cost of arabinoside-based and allogeneic stem-cell transplantation-based therapy in patients with acute leukaemia. The cost calculated from diagnosis to the end of therapy for patients who received allogeneic transplant was $76 423731 033. The cost out-ofpocket from diagnosis to the end of therapy was $10 30173.71, so the total cost of allogeneic transplantation was $86 724 (N ¼ 21).
The average value across these four studies, weighted according to the respective number of patients, is $105 842 or h94 350.
Lee et al. 24 have reported information also on the cost of autologous SCT. According to the these authors, the cost of autologous transplant was $55 500 per patient (range of $28 200-148 200; N ¼ 55), that is h49 474 (range of h25 138-132 109). In the absence of further information from the literature, these economic figures were applied to the nodonor group of our analysis.
Hence, if the average cost per patient is h94 350 for the donor group and h49 474 for the no-donor group, the incremental cost is h44 876 per patient.
From our literature search, very little information was found about the variations in the cost of allogeneic transplantation across different populations of patients. Only one study (Yu et al. 26 ) reported probabilistic data in the form of mean7s.d. ($86 724734 750) . According to these data, the coefficient of variation (CV) is 40%.
If one applies this CV of 40% to the average costs reported by Mishra et al. In this framework, $52 034 is the lowest value across the four estimates of the lower extreme and $162 562 is the highest value across the four estimates of the upper extreme. Despite our empirical design of this estimation of inter-subject variability, we considered this approximate calculation to be sufficient for the purposes of our sensitivity analysis and we therefore adopted $105 842 as an estimate of the average cost of allogeneic transplant and the range from $52 034 (or h46 385) to 162 562 (or h144 912) as an estimate of the 'typical' inter-subject variation of this cost figure.
Cost-effectiveness analysis
The clinical result calculated by our analysis showed a survival gain of about 1 year per patient, while our economic assessment found an incremental cost for allogeneic vs autologous transplant of h44 876 per patient. These two figures yield an incremental cost per life-year gained of h44 876.
In oncology, the gain of 1 year is valued at around h50 000 in terms of cost-effectiveness, 27 with an upper threshold around h80 000-100 000 or $80 000-100 000. Hence, our results indicate that allogeneic transplantation in these patients falls within the current international boundaries 27, 28 of cost-effectiveness (that is the cost per lifeyear gained is less than the upper threshold of h50 000).
Sensitivity analysis
If one keeps both the treatment cost of a control patient (h49 474 or $55 500) and the magnitude of the survival gain unchanged (1 year per patient) and introduces in the cost of allogeneic transplant a variation ranging from h46 385 (or $52 034) to h144 912 (or $162 562), the variation interval of the incremental cost ranges from a slightly negative incremental cost (hÀ3089 or $À3466 indicating that allogeneic may even be less costly than autologous) to a cost as high as h95 438 or $107 062. Using these data, the , which is assumed to be the reference for the other three studies. From top to bottom: the three data sets show the study-specific relative risk for the trials of Ribera et al. 3 (no statistically significant heterogeneity), Labar et al. 19 (no statistically significant heterogeneity) and Hunault et al.
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This latter study is statistically heterogeneous because its event-free survival pattern is significantly better than that of the reference study.
Outcomes in acute lymphoblastic leukaemia C Orsi et al variation around the 'central' value of the cost per life-year gained ranges from a negative result of hÀ3089 or $À3466 (indicating a so-called 'dominant result' because the experimental treatment is more effective and less costly) to h95 438 or $107 062, which is greater than the threshold of 50 000 but still less than the threshold of 100 000. Finally, one source of variability that could affect these cost-effectiveness results is the proportion of patients who actually underwent allogeneic SCT. Inasmuch as the overall proportion of subjects actually receiving allogeneic transplant was 76% in the four studies examined, one can reappraise our cost-effectiveness ratio by reducing the incremental cost of our primary analysis by 24%; in such a case, the cost per life-year reduces to h34 106 or $38 260.
Discussion
Our analysis showed that, in patients with ALL in CR1, allogeneic transplantation improves event-free survival as compared to autologous transplant or standard chemotherapy (Figures 1 and 2 ). This result had a marked statistical significance (P-value between 0.011 and 0.017); the magnitude of the mean survival benefit was clinically relevant (survival gain ¼ 1 year per patient).
Our assessment of heterogeneity based on four trials (Figure 3) identified the study by Hunault et al. 21 as a source of statistical heterogeneity (better event-free survival in Hunault's study-regardless of the treatment group-as compared with the other three trials). One explanation for this finding is that the event-free survival difference found between the two treatment groups by Hunault et al. (see for example their Figure 2d ) was the largest among the four trials included in our analysis (with a relative risk of less than 0.40 for Hunault's trial; see our Figure 2 ). In particular, while the controls of Hunault et al. fared similarly to those in the other three trials, the experimental group of the French authors had a markedly better outcome than the other three allogeneic transplant groups. Hunault et al. 21 have attributed their highly successful result in the allogeneic transplant arm to the high antileukaemic effect of their intensified conditioning regimen and to their low transplant-related mortality. This hypothesis is largely confirmed by our analysis and therefore deserves to be tested in further clinical trials.
In general, the statistical message generated by a metaanalysis is stronger when no heterogeneity is found. In the case of our analysis, the presence of some heterogeneity was anyhow helpful to better interpret the overall findings resulting from the various studies and to focus attention on Hunault's trial (which was, in fact, the main determinant, along with Thomas' study, of the superiority of allogeneic transplant; see our Figure 2 ).
After completion of our analysis but before submission of the present article, a meta-analysis similar to ours was published in this journal by Yanada et al. 5 Both our analysis and that of the Japanese authors concur in that, in these patients, allogeneic transplant provides a significant survival benefit (relative death risk in the study by Yanada et al. 5 ¼ 0.77; 95% CI: 0.61-0.98; P ¼ 0.04). The study of the Japanese authors had one limitation because their assessment was based only on abstracted data and no attempt was made to take into account the length of the follow-up or the timing of deaths. Our more complex survival model had an advantage because it incorporated the timing of individual events and therefore took into account the differences between early and late events (which have high clinical relevance inasmuch as the follow-up spanned over more than 10 years).
It can be seen that the meta-analytic relative risk calculated by Yanada et al. is nearly identical to that generated by our analysis. However, in the Japanese study, early and late deaths were given the same statistical weight (because of their crude-rate approach and their lack of adjustment for timing of events). Since this bias could have influenced the results of Yanada et al. in a situation where early events (that is transplant-related deaths) are known to be more frequent in the experimental arm, our confirmation based on a statistical model not affected by this bias is important.
The incorporation of time into our statistical model brought about another advantage because our analysis was able to estimate the magnitude of the mean survival gain (1 year per patient) and therefore allowed us to carry out a simplified cost-effectiveness assessment. The cost-effectiveness result of our study is of interest because allogeneic transplant showed very favourable levels of cost per lifeyear gained. Although our cost-effectiveness analysis contained some approximations regarding cost data, the cost per life-year gained was found to be within the current threshold of economic acceptance, and even our 'extreme' sensitivity analysis found a result below the threshold of h100 000 per life-year gained.
In conclusion, both our survival meta-analysis and the one recently published by Yanada et al. 5 are highly consistent in indicating that, when a donor is available, allogeneic SCT is the treatment of choice for patients with ALL in CR1. The cost effectiveness profile remains well within the current standards for innovative oncologic treatments. 27, 28 
